Related Experiment Video
Updated: Aug 20, 2026
Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway
Cali Loblundo1,2, Sammy Y Gao1,3, Shaun A Nguyen1
1Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Objective:
To evaluate glucagon-like peptide 1 receptor agonists for obstructive sleep apnea compared with controls.
Data Sources:
CINAHL, Cochrane Library, PubMed, and Scopus.
Review Methods:
A PRISMA-compliant search was conducted from database inception through October 2025. Randomized controlled trials evaluating glucagon-like peptide 1 receptor agonist use (liraglutide and tirzepatide) for obstructive sleep apnea were included. The primary outcome was the change in apnea-hypopnea index. Data on apnea-hypopnea index, body weight, waist circumference, blood pressure, inflammatory markers, and adverse events were extracted and stratified by continuous positive airway pressure use. Outcomes were summarized as mean differences (Δ) with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane Risk of Bias 2 tool.
Results:
Of 3,836 articles screened, five studies met the inclusion criteria, comprising 948 patients (479 GLP-1; 469 control). Glucagon-like peptide 1 receptor agonists reduced apnea-hypopnea index by 12.4 events/hour more than controls (95% CI: -17.2 to -7.7; P < .00001), independent of continuous positive airway pressure use. Glucagon-like peptide 1 receptor agonists produced greater weight loss (Δ: -12.5%; 95% CI: -22.0% to -3.0%; P = .01) and reduced waist circumference (Δ: -3.3 cm; 95% CI: -4.4 to -3.2; P < .00001). Systolic and diastolic blood pressure decreased by 4.5 mmHg (95% CI: -6.4 to -2.7) and 1.30 mmHg (95% CI: -2.59 to -0.01), respectively. Gastrointestinal adverse events were more common with glucagon-like peptide 1 receptor agonists.
Conclusion:
Glucagon-like peptide 1 receptor agonists produced clinically meaningful improvements in obstructive sleep apnea severity, independent of continuous positive airway pressure use.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:30Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...